ArticleFrontiers in immunology2022
NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Hongxia Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this paperpooled itcites it